Hua-Xin Liao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6162241/publications.pdf

Version: 2024-02-01

82 papers	7,367 citations	71102 41 h-index	60623 81 g-index
82 all docs	82 docs citations	82 times ranked	6944 citing authors

#	Article	IF	Citations
1	Allelic imbalance of HLA-B expression in human lung cells infected with coronavirus and other respiratory viruses. European Journal of Human Genetics, 2022, , .	2.8	10
2	Genome-wide identification of key regulatory lncRNAs in esophageal cancer metastasis. Signal Transduction and Targeted Therapy, 2021, 6, 88.	17.1	15
3	Structural basis of tetanus toxin neutralization by native human monoclonal antibodies. Cell Reports, 2021, 35, 109070.	6.4	10
4	Exploiting Pre-Existing CD4+ T Cell Help from Bacille Calmetteâ€“GuÃ©rin Vaccination to Improve Antiviral Antibody Responses. Journal of Immunology, 2020, 205, 425-437.	0.8	3
5	Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunology, Immunotherapy, 2020, 69, 1375-1387.	4.2	75
6	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. Nature Immunology, 2020, 21, 199-209.	14.5	68
7	A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme . Cancer Management and Research, 2019, Volume 11, 8977-8989.	1.9	6
8	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008026.	4.7	56
9	Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. Viruses, 2019, 11, 159.	3.3	13
10	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. Nature Communications, 2019, 10, 654.	12.8	34
11	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology, 2018, 92, .	3.4	46
12	Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. Journal of Virology, 2018, 92, .	3.4	30
13	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	3.4	10
14	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology, 2018, 92, .	3.4	45
15	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. Journal of Virology, 2018, 92, .	3.4	24
16	Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59Â®-adjuvanted pandemic 2009 H1N1 vaccine. Vaccine, 2018, 36, 5325-5332.	3.8	4
17	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. Journal of Experimental Medicine, 2018, 215, 1571-1588.	8.5	366
18	Antibodyâ€virus coâ€evolution in <scp>HIV</scp> infection: paths for <scp>HIV</scp> vaccine development. Immunological Reviews, 2017, 275, 145-160.	6.0	160

#	Article	IF	Citations
19	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2, .	11.9	119
20	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	6.4	69
21	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nature Communications, 2017, 8, 15711.	12.8	137
22	Staged induction of HIV-1 glycanâ€“dependent broadly neutralizing antibodies. Science Translational Medicine, 2017, 9, .	12.4	212
23	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine, 2017, 9, .	12.4	81
24	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. AIDS Research and Human Retroviruses, 2017, 33, 859-868.	1.1	18
25	Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. Journal of Virological Methods, 2017, 249, 85-93.	2.1	2
26	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Journal of Virology, 2017, 91, .	3.4	19
27	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. Journal of Virology, 2017, 91, .	3.4	29
28	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS ONE, 2017, 12, e0176428.	2.5	12
29	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	12.8	76
30	Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight, 2017, 2, .	5.0	11
31	Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. Nature Communications, 2016, 7, 12131.	12.8	14
32	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	8.2	41
33	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine, 2016, 14, 97-111.	6.1	47
34	HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. Immunogenetics, 2016, 68, 145-155.	2.4	18
35	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Cell Reports, 2016, 15, 1505-1513.	6.4	43
36	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2016, 35, 217-226.	1.6	9

#	Article	IF	Citations
37	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. Journal of Immunology, 2016, 197, 4663-4673.	0.8	6
38	Initiation of immune toleranceâ€“controlled HIV gp41 neutralizing B cell lineages. Science Translational Medicine, 2016, 8, 336ra62.	12.4	86
39	Immune perturbations in HIV-1â€“infected individuals who make broadly neutralizing antibodies. Science Immunology, 2016, 1, aag0851.	11.9	120
40	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nature Medicine, 2016, 22, 1465-1469.	30.7	104
41	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 2016, 12, 196-207.	6.1	34
42	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. Journal of Virology, 2016, 90, 5031-5046.	3.4	38
43	Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. Cancer Immunology, Immunotherapy, 2016, 65, 171-180.	4.2	16
44	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell, 2016, 165, 449-463.	28.9	305
45	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. Journal of Virology, 2016, 90, 4951-4965.	3.4	23
46	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Reports, 2016, 14, 43-54.	6.4	45
47	Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. PLoS ONE, 2016, 11, e0157391.	2.5	33
48	Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. Cell Reports, 2015, 13, 2842-2850.	6.4	67
49	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Viruses, 2015, 7, 5443-5475.	3.3	26
50	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	4.7	145
51	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	3.4	40
52	Diversion of HIV-1 vaccineâ€“induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015, 349, aab1253.	12.6	191
53	Viral Receptor-Binding Site Antibodies with Diverse Germline Origins. Cell, 2015, 161, 1026-1034.	28.9	151
54	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. Journal of Virology, 2015, 89, 9952-9961.	3.4	55

#	Article	IF	Citations
55	Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. Journal of Virology, 2015, 89, 8245-8257.	3.4	99
56	Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. Journal of Virology, 2015, 89, 9485-9498.	3.4	8
57	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine, 2015, 2, 713-722.	6.1	13
58	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	11.0	66
59	Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. Journal of Infectious Diseases, 2015, 211, 947-955.	4.0	140
60	Progress in HIV-1 vaccine development. Journal of Allergy and Clinical Immunology, 2014, 134, 3-10.	2.9	62
61	Estimating the Probability of Polyreactive Antibodies 4E10 and 2F5 Disabling a gp41 Trimer after T Cell-HIV Adhesion. PLoS Computational Biology, 2014, 10, e1003431.	3.2	3
62	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. Frontiers in Immunology, 2014, 5, 170.	4.8	104
63	Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10275-10280.	7.1	73
64	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology, 2014, 88, 7715-7726.	3.4	169
65	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. Immunity, 2014, 41, 909-918.	14.3	65
66	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAXÂ® B/E in RV144 Vaccinees. AIDS Research and Human Retroviruses, 2014, 30, A36-A36.	1.1	1
67	Envelope Glycoprotein Binding to the Integrin Î± ₄ Î² ₇ Is Not a General Property of Most HIV-1 Strains. Journal of Virology, 2014, 88, 10767-10777.	3.4	25
68	IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. PLoS ONE, 2014, 9, e90725.	2.5	37
69	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology, 2014, 88, 9406-9417.	3.4	16
70	CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies. Journal of Virology, 2014, 88, 6542-6555.	3.4	55
71	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. Cell Host and Microbe, 2014, 16, 215-226.	11.0	105
72	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	28.9	266

#	Article	IF	Citations
73	Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. Journal of Virology, 2013, 87, 4185-4201.	3.4	83
74	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013, 496, 469-476.	27.8	961
75	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	14.3	374
76	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. Journal of Experimental Medicine, 2011, 208, 2237-2249.	8.5	198
77	High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. Journal of Virological Methods, 2009, 158, 171-179.	2.1	235
78	Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology, 2009, 394, 91-98.	2.4	28
79	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. Journal of Virology, 2008, 82, 12449-12463.	3.4	548
80	A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology, 2006, 353, 268-282.	2.4	176
81	Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins. Journal of Virology, 2004, 78, 5270-5278.	3.4	40
82	HIV Vaccine Development at Duke University Medical Center. Immunologic Research, 2000, 22, 263-270.	2.9	0